timolol 0.5% BID — Competitive Intelligence Brief

timolol 0.5% BID (timolol 0.5% BID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-selective beta-adrenergic receptor blocker. Area: Ophthalmology.

phase 3 Non-selective beta-adrenergic receptor blocker Beta-adrenergic receptors Ophthalmology Small molecule

Target snapshot

timolol 0.5% BID (timolol 0.5% BID) — Inotek Pharmaceuticals Corporation. Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
timolol 0.5% BID TARGET	timolol 0.5% BID	Inotek Pharmaceuticals Corporation	phase 3	Non-selective beta-adrenergic receptor blocker	Beta-adrenergic receptors
ISOPROTERENOL	ISOPROTERENOL		marketed	Beta-adrenergic agonist	beta-adrenergic receptors	1956-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Xalatan+Cosopt	Xalatan+Cosopt	University of Turin, Italy	marketed	Prostaglandin analog + carbonic anhydrase inhibitor + beta-blocker combination	Prostaglandin F receptor (FP receptor); carbonic anhydrase II; beta-adrenergic receptors
intralesional propranolol injection	intralesional propranolol injection	Ain Shams University	marketed	Beta-adrenergic antagonist	Beta-adrenergic receptors (non-selective)
Cosopt PF 2%-0.5% Ophthalmic Solution	Cosopt PF 2%-0.5% Ophthalmic Solution	Prairie Eye Center	marketed	Fixed-dose combination of carbonic anhydrase inhibitor and beta-blocker	Carbonic anhydrase II (dorzolamide component); beta-adrenergic receptors (timolol component)
dorzolamide/timolol maleate fixed combination	dorzolamide/timolol maleate fixed combination	Pharmaceutical Research Network	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2)

Recent regulatory actions (last 90 days)

• 2026-03-26 — Norepinephrine Bitartrate In 5% Dextrose · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-selective beta-adrenergic receptor blocker class)

1. Inotek Pharmaceuticals Corporation · 1 drug in this class